Base to Base biotech podcast 2: Opioid alternatives and epiproteomics

Our guest, Dr. Hernan Bazan, is the CEO and co-founder of South Rampart Pharma. He is also a board-certified vascular surgeon.Bazan is also the recipient of the 2024 NIH HEAL (Helping to End Addiction Long-term) Director's Trailblazer Award for his work in developing a non-addictive pain medication as an alternative to opioids.At South Rampart Pharma, he is leading the development of SRP-001, a new type of pain medication that lacks the addictive potential of opioids and avoids safety and toxicity issues associated with other pain medications.SRP-001 has already received FDA Fast Track designation and was not associated with any serious adverse events (SAEs) in a Phase 1 clinical trial. The company is currently preparing to initiate its Phase 2 trial in the second quarter of 2025.Promise BioWe also have a conversation with Ronel Veksler, the co-founder and CEO of Promise Bio, whose AI-driven system combines multi-omics data analysis with proprietary machine learning algorithms to identify unique biomarkers and disease pathways, enabling early, precise diagnosis and personalized treatment strategies for autoimmune conditions.The company recently secured $8.3m in seed investment, with backing from Pfizer and AstraZeneca and has been recognized by TechCrunch as one of the most disruptive scientific startups of 2024.

There are no comments yet.

Please log in to write the first comment.